identif
pathogen
mainli
includ
viru
isol
viral
nucleic
acid
detect
accord
tradit
koch
postul
viru
isol
gold
standard
viru
diagnosi
laboratori
first
viral
cultur
prerequisit
diagnos
viral
infect
varieti
specimen
swab
nasal
swab
nasopharynx
trachea
extract
sputum
lung
tissu
blood
fece
retain
test
time
manner
give
higher
rate
posit
detect
lower
respiratori
tract
specimen
immunolog
method
e
includ
immunofluoresc
assay
protein
microarray
direct
fluoresc
antibodi
assay
mabbas
rapid
np
nucleocapsid
protein
detect
semiconductor
quantum
dot
microneutr
test
e
measur
bind
antigen
whole
viru
protein
coronaviru
correspond
antibodi
easi
oper
rapidli
lower
sensit
specif
addit
immunolog
method
includ
microneutr
ppnt
assay
pseudoparticl
neutral
highli
sensit
specif
use
gene
code
coronaviru
spike
protein
case
viral
research
institut
conduct
preliminari
identif
viru
classic
koch
postul
observ
morpholog
electron
microscopi
serolog
could
also
use
identifi
viru
antigen
monoclon
antibodi
develop
futur
exampl
tradit
viru
detect
method
viral
nucleic
acid
also
use
earli
diagnosi
follow
new
coronaviru
detect
method
polymeras
chain
reaction
pcr
molecular
biolog
diagnosi
technolog
base
sequenc
nucleic
acid
full
gene
sequenc
obtain
patient
suspect
infect
diagnos
pancoronaviru
pcr
viru
identif
revers
transcript
polymeras
chain
reaction
rtpcr
technolog
combin
rna
revers
transcript
rt
polymeras
chain
amplif
pcr
cdna
duplex
rtpcr
assay
use
detect
sarscov
merscov
use
templat
respect
also
sampl
collect
upper
respiratori
tract
oropharyng
nasopharyng
lower
respiratori
tract
endotrach
aspir
expector
sputum
bronchoalveolar
lavag
suspect
patient
diagnos
rtpcr
revers
transcriptioninsul
isotherm
polymeras
chain
reaction
rtiipcr
quantit
realtim
revers
transcript
polymeras
chain
reaction
qrtpcr
realtim
rtpcr
rtrtpcr
onestep
rtrtpcr
optim
optim
rtpcr
method
use
detect
merscov
envelop
gene
upe
open
read
frame
open
read
frame
gene
separ
howev
rtrtpcr
use
identifi
preliminari
valid
detect
e
gene
rnadepend
rna
polymeras
rdrp
gene
n
gene
molecularbas
detect
techniqu
addit
rtpcr
similar
optim
detect
techniqu
exampl
revers
transcript
loopmedi
isotherm
amplif
rtlamp
rna
amplif
techniqu
detect
n
gene
merscov
gene
onepot
revers
transcript
loopmedi
isotherm
amplif
onepot
rtlamp
optim
rtlamp
rtlampvf
deform
rtlamp
combin
revers
transcript
loopmedi
isotherm
amplif
vertic
flow
visual
strip
use
detect
n
gene
merscov
make
detect
easier
faster
effici
highli
specif
besid
three
method
revers
transcript
recombinas
polymeras
amplif
assay
rtpra
also
use
identifi
merscov
final
follow
multiplex
test
detect
coronavirus
virus
mcovm
multiplex
cov
mass
spectrometri
use
array
matrixassist
laser
desorptionion
timeofflight
mass
spectrometri
malditof
ms
system
accur
identifi
known
human
coronavirus
hcov
provid
phylogenet
evid
emerg
unknown
hcov
anoth
new
test
method
archshap
multipletarget
sensor
use
amplifi
target
rapid
identif
pathogen
clinic
sampl
method
detect
hcov
zika
ebola
virus
last
one
paperbas
colorimetr
assay
use
pyrrolidinyl
peptid
nucleic
acidinduc
silver
nanoparticl
agnp
aggreg
pathogen
dna
test
color
chang
agnp
distinguish
merscov
mycobacterium
tuberculosi
mtb
human
papillomaviru
hpv
cellular
receptor
sarscov
merscov
identifi
virion
spike
glycoprotein
also
well
studi
glycoprotein
includ
two
subunit
result
cleavag
one
precursor
two
part
determin
viru
host
rang
cellular
tropism
key
function
domain
receptor
bind
domain
rbd
contain
two
tandem
domain
heptad
repeat
heptad
repeat
mediat
viruscel
membran
fusion
believ
fusion
process
similar
exampl
bind
receptor
cell
membran
fusion
peptid
n
terminu
insert
cell
membran
three
attach
parallel
trimer
follow
bind
three
separ
onto
outsid
trimer
form
bundl
thu
bring
viru
cell
membran
close
trigger
fusion
major
vaccin
target
protein
evalu
differ
type
vaccin
infect
cov
apart
inact
whole
viru
particl
live
attenu
viru
gene
delet
four
vaccin
mainli
contain
protein
studi
includ
viruslik
particl
incorpor
protein
hepat
viru
influenza
viru
protein
viru
vector
modifi
vaccinia
viru
ankara
mva
adenoviru
carri
protein
protein
subunit
vaccin
like
rbdbase
protein
dna
vaccin
encod
full
length
part
protein
gene
test
mous
model
show
abil
elicit
neutral
antibodi
first
sarscov
dna
vaccin
test
human
month
viru
sequenc
publish
dna
vaccin
first
merscov
vaccin
went
clinic
trial
addit
convent
vaccin
liu
et
al
analyz
cell
epitop
sarscov
merscov
reveal
potenti
crossreact
coronavirus
assess
possibl
develop
univers
vaccin
coronaviru
infect
cov
share
similar
viral
structur
similar
infect
pathway
similar
structur
protein
suggest
similar
research
strategi
also
applic
exampl
studi
merscov
vaccin
acceler
virtu
strategi
establish
sarscov
report
also
genet
close
sarscov
therefor
predict
whether
vaccin
develop
sarscov
also
effect
infect
full
length
protein
sequenc
sarscov
two
genet
similar
bat
cov
strain
select
align
fig
result
indic
homolog
virus
howev
variabl
residu
locat
critic
vaccin
target
impli
neutral
antibodi
effect
sarscov
infect
may
fail
recogn
multipl
amino
acid
differ
receptor
bind
motif
may
modifi
viru
tropism
possibl
reason
crossspeci
transmiss
howev
sever
bottleneck
typic
delay
approv
vaccin
prevent
cov
infect
first
lack
proper
anim
model
evalu
vaccin
efficaci
second
limit
protein
mutat
neutral
antibodi
epitop
protein
caus
viru
escap
nonneutr
antibodi
epitop
vaccin
may
elicit
antibodymedi
diseas
enhanc
ade
third
dna
vaccin
may
recombin
virus
fourth
preexist
immun
may
elimin
vaccin
remov
gener
human
viru
vector
final
problem
return
invest
may
slow
henc
inhibit
invest
slow
clinic
studi
jiang
colleagu
demonstr
rbd
sarscov
protein
major
target
neutral
antibodi
sar
patient
abl
induc
highli
potent
neutral
antibodi
respons
longterm
protect
immun
anim
model
contain
differ
conform
neutral
epitop
seri
mous
monoclon
antibodi
mab
differ
neutral
activ
gener
interestingli
mab
exhibit
crossneutr
activ
diverg
sarscov
strain
isol
sar
patient
differ
stage
sar
epidem
palm
civet
group
also
shown
sarscovrbdspecif
neutral
mab
crossneutr
bat
slcov
bat
indic
antibodi
may
also
crossneutr
importantli
rbdbase
vaccin
could
induc
neutral
antibodi
respons
protect
sarscov
infect
immun
anim
elicit
ade
harm
immun
respons
unlik
virusinactiv
vaccin
fulllength
proteinbas
vaccin
discuss
therefor
rbdbase
sar
vaccin
expect
safer
effect
vaccin
target
site
protein
jiang
du
group
collabor
hotez
group
baylor
colleg
medicin
houston
tseng
group
univers
texa
medic
branch
galveston
texa
usa
develop
effect
safe
vaccin
late
stage
preclin
studi
antibodi
induc
vaccin
candid
expect
crossneutr
infect
confirm
vaccin
candid
great
potenti
develop
promptli
clinic
trial
china
unit
state
continu
collabor
among
four
group
dr
hotez
tseng
du
jiang
present
specif
antivir
therapi
approv
treatment
infect
human
cov
develop
vaccin
compound
prevent
treatment
infect
brought
prioriti
statu
govern
numer
drug
studi
done
move
forward
focu
cov
fusionentri
process
either
inhibit
mediat
viru
attach
block
mediat
viruscel
membran
fusion
interfer
viral
replic
base
previou
experi
develop
fusion
inhibitor
jiang
et
al
discov
first
antisarscov
peptid
domain
sarscov
protein
subunit
could
bind
onto
domain
form
sixhel
bundl
block
proteinmedi
membran
fusion
inhibit
sarscov
infect
merscov
circul
human
popul
follow
similar
mechanist
design
jiang
research
group
develop
anoth
peptid
design
deriv
viru
region
well
effect
inhibit
merscov
infect
modifi
version
present
even
better
antimerscov
activ
pharmaceut
properti
develop
broadspectrum
pancov
fusion
inhibitor
would
ideal
way
cope
epidem
pandem
caus
emerg
hcov
conserv
amino
acid
sequenc
region
across
differ
cov
potenti
target
domain
develop
inhibitor
continu
work
domain
jiang
group
discov
peptid
deriv
domain
broadli
inhibit
fusion
multipl
hcov
optim
peptid
pancov
fusion
inhibitor
gener
could
form
stabl
sixhelix
bundl
structur
show
significantli
improv
fusioninhibitori
activ
pharmaceut
properti
align
protein
fig
exhibit
ident
domain
sarscov
howev
found
amino
acid
chang
fusion
core
locat
bind
motif
fortun
substitut
conserv
replac
would
dramat
disrupt
interact
mean
would
still
potenti
effect
inhibitor
infect
far
neutral
antibodi
recogn
rbd
protein
cov
compar
high
mutat
rate
protein
much
conserv
therebi
decreas
offtarget
risk
caus
amino
acid
replac
also
bypass
special
epitop
may
caus
ade
mean
cocktail
monoclon
antibodi
bind
differ
epitop
rbd
would
desir
therapeut
purpos
treatment
monoclon
antibodi
human
sourc
human
antibodi
isol
gener
variou
approach
exampl
wildtyp
mice
immun
solubl
recombin
rbd
contain
protein
mous
antibodi
human
isol
transgen
mice
directli
immun
express
human
version
antibodi
howev
direct
clone
singl
b
cell
human
survivor
use
combin
phagedisplay
antibodi
librari
could
provid
authent
human
antibodi
note
mani
neutral
antibodi
success
discov
treatment
sarscov
merscov
infect
antibodi
describ
favor
literatur
similar
approach
known
singl
chain
fragment
variabl
scfv
librari
screen
wherebi
use
rbd
bait
protein
allow
neutral
antibodi
screen
nonimmun
human
antibodi
effect
inhibit
sarscov
infect
also
potenti
treatment
well
long
bind
motif
rbd
share
sequenc
new
neutral
monoclon
antibodi
would
also
isol
patient
use
establish
techniqu
similar
develop
vaccin
drug
effect
rna
virus
also
repurpos
cov
two
major
type
drug
nucleosid
analogu
immunomodul
far
common
therapi
tri
patient
cov
ribavirin
lopinavirritonavir
ifn
combin
despit
antivir
activ
observ
vitro
studi
clinic
effect
consist
ribavirin
prolong
surviv
sarscov
patient
lopinavirritonavir
plu
ribavirin
seem
improv
clinic
outcom
sar
patient
improv
confirm
merscov
patient
ifn
show
effect
induc
antivir
activ
sarscov
mrescov
without
signific
improv
outcom
patient
addit
drug
regimen
use
patient
numer
drug
develop
treatment
infect
cov
thoroughli
discuss
literatur
howev
replic
rna
viru
usual
gener
progeni
virus
highli
divers
genom
recombin
also
easili
take
place
viral
genom
gene
level
chang
may
result
drug
resist
mutat
affect
drug
target
domain
develop
drug
also
hamper
variou
evalu
method
anim
model
use
test
drug
activ
among
differ
lab
worldwid
could
postpon
select
best
drug
clinic
trial
taken
togeth
new
coronaviru
like
sarscov
merscov
belong
betacoronaviru
sarscov
merscov
abl
spread
around
globe
pose
major
challeng
clinic
manag
great
threat
public
health
similarli
sarscov
merscov
base
monitor
scientif
forecast
may
caus
worldwid
threat
public
health
year
research
cov
result
multipl
strategi
diagnosi
prevent
treatment
cov
infect
brief
review
demonstr
achiev
could
well
appli
inde
newli
emerg
cov
futur
present
mani
compani
engag
develop
biolog
market
nucleic
acid
detect
kit
new
coronaviru
nucleic
acid
detect
kit
doubl
fluoresc
pcr
method
shuoshi
biotechnolog
current
howev
diagnost
test
kit
avail
detect
antibodi
author
declar
conflict
interest
